Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXi4503 in hepatic tumor burden carcinomas
ACTRN12609000253202Phase 2Completed
- Sponsor
- Clinical Network Services
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxi-4503 in hepatocellular carcinoma (HCC) and carcinoma, sponsored by Clinical Network Services. Primary endpoints: Safety and tolerability, Maximum tolerated dose and 1 more. Started Mar 2009; status: completed.
02
Drugs
oxi-4503
03
Conditions
hepatocellular carcinoma (HCC)carcinoma
Beyond the preview
Go deeper on ACTRN12609000253202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000253202.